Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals's GHG Emissions Data Preview
In 2024, Regeneron Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Regeneron Pharmaceuticals has also provided a category-level breakdown for 7 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Regeneron Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Regeneron Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Regeneron Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Regeneron Pharmaceuticals amounted to 137,300 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Regeneron Pharmaceuticals increased by 11.9%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
Regeneron Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Regeneron Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Regeneron Pharmaceuticals were 80,300 metric tons of CO₂ equivalent (tCO₂e). a
Has Regeneron Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2018, Regeneron Pharmaceuticals's Scope 1 emissions have increased by 37.97%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2023), Regeneron Pharmaceuticals's Scope 1 emissions increased by 15.37%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Regeneron Pharmaceuticals's Scope 2 emissions?
In 2024, Regeneron Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 40,400 tCO₂e using the market-based method and 57,000 tCO₂e using the location-based method. a
Has Regeneron Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2018, Regeneron Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions ( Location-Based) have increased by 37.68%, reflecting a rising long-term trend in Scope 2 emissions over time. a b
Compared to the previous year (2023), Regeneron Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Regeneron Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does Regeneron Pharmaceuticals use for Scope 2 reporting?
In 2024, Regeneron Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method. a
Regeneron Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into Regeneron Pharmaceuticals's Value Chain Emissions
In 2024, Regeneron Pharmaceuticals reported 1,344,820 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of Regeneron Pharmaceuticals includes a breakdown across 7 of the 15 Scope 3 categories defined by the GHG Protocol, up from 6 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chain a
Regeneron Pharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Regeneron Pharmaceuticals's Scope 3 emissions?
In 2024, Regeneron Pharmaceuticals reported total Scope 3 emissions of 1,344,820 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment. a
Has Regeneron Pharmaceuticals reduced its Scope 3 emissions over time?
Since 2018, Regeneron Pharmaceuticals's Scope 3 emissions have increased by 240.83%, reflecting a rising long-term trend in Scope 3 emissions over time. a b
Compared to the previous year (2023), Regeneron Pharmaceuticals's Scope 3 emissions increased by 54.07%, suggesting that the company faced challenges in reducing emissions across its value chain. a
What categories of Scope 3 emissions does Regeneron Pharmaceuticals disclose?
In 2024, Regeneron Pharmaceuticals reported emissions for 7 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Regeneron Pharmaceuticals's Scope 3 emissions?
In 2024, the largest contributors to Regeneron Pharmaceuticals's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 1,106,777 tCO₂e (82.3%)
- Capital Goods (Cat. 2): 112,166 tCO₂e (8.34%)
- Fuel- and Energy-Related Services (Cat. 3): 40,943 tCO₂e (3.04%)
Regeneron Pharmaceuticals's Scope 3 Emissions by Categories
Insights into Regeneron Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Regeneron Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 80,300 tCO₂e and total revenues of USD 14,202 millions. This translates into an emissions intensity of 5.65 tCO₂e per millions USD. a
Regeneron Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Regeneron Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, Regeneron Pharmaceuticals reported a Scope 1 emissions intensity of 5.65 tCO₂e per millions USD. Compared to the peer group median of 2.64 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
Where does Regeneron Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, Regeneron Pharmaceuticals ranked 21 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places Regeneron Pharmaceuticals among the least efficient performers, with one of the highest emissions intensities in its sector. a
Insights into Regeneron Pharmaceuticals's Total Carbon Footprint
In 2024, Regeneron Pharmaceuticals reported a total carbon footprint of 1,482,120 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 48.87% increase compared to 2023, suggesting a rise in emissions across its operations or value chain. a
The largest contributor to Regeneron Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 90.74% of the company's total carbon footprint, followed by Scope 1 emissions at 5.42%. a